Skip to main content

Valsartan, Losartan and Irbesartan Use in the USA, UK, Canada and Denmark After the Nitrosamine Recalls: A Descriptive Cohort Study

Basic Details
Date
Type
Publication
Description

We sought to examine valsartan, losartan and irbesartan usage and switching patterns in the United States of America, United Kingdom, Canada and Denmark before and after July 2018, when the first Angiotensin-Receptor-Blocker (ARB) (valsartan) was recalled. This retrospective cohort study included patients aged 18 years and older.

Materials

BMJ Open 2023 April 17. doi.org/10.1136/bmjopen-2022-070985

Related Assessment(s)
Presentation: Impact of Nitrosamine Contamination Recalls on Angiotensin-Receptor-Blocker (ARB) Utilization in the U.S., U.K., Canada, and Denmark
Sentinel Drug Analysis: Utilization of Valsartan: A Descriptive Analysis
Author(s)

Efe Eworuke, Mayura Shinde, Laura Hou, Michael J Paterson, Peter Bjødstrup Jensen, Judith C Maro, Ashish Rai, Daniel Scarnecchia, Dinci Pennap, Daniel Woronow, Rebecca E Ghosh, Stephen Welburn, Anton Pottegard, Robert W Platt, Hana Lee, Marie C Bradley

Corresponding Author

Efe Eworuke; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.

Email: efeeworuke@gmail.com